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Highlights 
•! Cip-encapsulated, in-situ crosslinked wet spun collagen fibres were accomplished  
•! In-situ Ph-crosslinked fibres displayed the highest tensile modulus  
•! Nanoscale aromatic interactions proved key to control Cip release  
•! Fibre morphology was not affected by drug encapsulation and in-situ crosslinking  
 
Abstract 
The design of antibacterial-releasing coatings or wrapping materials with controlled drug 
release capability is a promising strategy to minimise risks of infection and medical device 
failure in vivo. Collagen fibres have been employed as medical device building block, 
although they still fail to display controlled release capability, competitive wet-state 
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mechanical properties, and retained triple helix organisation. We investigated this challenge 
by pursuing a multiscale design approach integrating drug encapsulation, in-situ covalent 
crosslinking and fibre spinning. By selecting ciprofloxacin (Cip) as a typical antibacterial 
drug, wet spinning was selected as a triple helix-friendly route towards Cip-encapsulated 
collagen fibres; whilst in-situ crosslinking of fibre-forming triple helices with 
1,3-phenylenediacetic acid (Ph) was hypothesised to yield Ph-Cip π-π stacking aromatic 
interactions and enable controlled drug release. Higher tensile modulus and strength were 
measured in Ph-crosslinked fibres compared to state-of-the-art carbodiimide-crosslinked 
controls. Cip-encapsulated Ph-crosslinked fibres revealed decreased elongation at break and 
significantly-enhanced drug retention in vitro with respect to Cip-free variants and 
carbodiimide-crosslinked controls, respectively. This multiscale manufacturing strategy 
provides new insight aiming at wet spun collagen triple helices with nanoscale-regulated 
tensile properties and drug release capability.   
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1.! Introduction 
Bacterial infection is one of the most common causes of medical implant failure. 
Pathogenic micro-organisms are found in approximately 90% implants [1], potentially 
leading to bone infection, such as osteomyelitis. Here, the use of fluoroquinolones is an 
established systemic therapeutic approach. Ciprofloxacin (Cip) has been the most widely 
used fluoroquinolone to treat bacterial bone infection, due to its low (0.25–2 µg/mL) minimal 
inhibitory concentration (MIC) for most osteomyelitis-related pathogens [2]. The design of 
a medical device coating or bone wrap capable of delivering Cip in a controlled and localised 
manner is therefore an appealing strategy to minimise risks of osteomyelitis. 
Collagen-based fibres have been widely manufactured for biomedical applications 
due to their inherent biomimetic features at multiple length scales [3]. In light of collagen’s 
hierarchical organisation, bespoke fibre spinning approaches have successfully been 
developed to realise mechanically-competitive wet spun collagen fibres [4], highly ordered 
structures [5], and nonwoven collagen-based assemblies [6]. These building blocks could be 
applied as delivery system of antibacterial drugs or used to wrap existing medical devices, 
delivering a cost-effective infection control strategy. In light of the high compatibility with 
water, however, collagen-based fibres often display limited structural stability [7] and drug 
delivery capability [8], whereby antibacterial drugs, e.g. Cip, are released fast, typically 
within minutes [9]. To achieve durable antibacterial release and minimise risks of infection-
induced failure of medical devices, multiscale mechanisms of collagen fibre spinning and 
drug-fibre complexation are key.  
This study investigated the design of Cip-encapsulated fibres via a multiscale integrated 
process of collagen triple helix (CTH) wet spinning and in-situ crosslinking. We 
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hypothesised that nanoscale aromatic interactions could be introduced between fibre-forming 
covalently-crosslinked collagen triple helices and Cip, aiming at enhanced fibre spinnability, 
mechanical compliance and drug delivery capability. In-situ crosslinking was pursued during 
wet spinning of Cip-encapsulated collagen suspensions via either CTH functionalisation with 
1,3-phenylenediacetic acid (Ph) or control carbodiimide-mediated condensation reaction. 
Resulting wet spun fibres were assessed with respect to lysine functionalisation, surface 
morphology, tensile properties, drug release capability and hydrolytic degradability.  
 
2.!Materials and methods 
2.1 Materials 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
N-hydroxysuccinimide (NHS), Ph, and β-mercaptoethanol (βME) were purchased from Alfa 
Aesar. Cip was purchased from Cambridge Bioscience. 2,4,6-trinitrobenzenesulfonic acid 
(TNBS), acetic acid and Dulbecco's Phosphate Buffered Solution (PBS) were purchased from 
Sigma Aldrich. 
 
2.2 Drug encapsulation, in-situ crosslinking and wet spinning  
In-house extracted rat tail collagen suspensions were prepared (1.2 % wt./vol.) in 17.4 
mM acetic acid [4]. Three in-situ crosslinking strategies were pursued: (i) Ph- and EDC-
mediated network formation, (ii) Ph-mediated network formation, and (iii) state-of-the-art 
carbodiimide-mediated condensation reaction control. In (i), Ph (4 mg) was dissolved in the 
collagen suspension (3 ml) and an equimolar amount (0.01 M) of EDC and NHS was added 
prior to wet spinning [4]. In (ii), Ph, EDC and NHS were added as previously reported, whilst 
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an equimolar amount of βME (with respect to EDC) was added to quench EDC and stirred 
for 30 min prior to wet spinning. In (iii), an equimolar content (0.01 M) of EDC and NHS 
was dissolved in the collagen suspension prior to wet spinning. Cip-encapsulated fibres were 
obtained according to (i-iii), whereby 15 μg∙ml-1 Cip was added to the collagen suspension 
prior to addition of the crosslinking agents. Crosslinking occurrence was assessed via TNBS 
assay (n=3) [10]. 
 
2.3 Tensile tests and scanning electron microscopy of wet spun collagen fibres 
Tensile tests were carried out (0.03 mm·s-1, 18 ℃, 38 % r.h.) on individual collagen fibres 
(n=10) using a Zwick Roell Z010 apparatus equipped with a 10 N load cell. Tensile 
measurements were reported as mean ± standard deviation. Fibre surface morphology was 
inspected using a Hitachi SU8230 FESEM, with a beam intensity of 10 kV after gold 
sputtering using a JFC-1200 fine sputter coater. 
 
2.4 Drug release and degradation tests 
In-situ crosslinked wet spun fibres (n=3) of known weight were individually stored in 
centrifuge tubes containing 5 ml PBS at 37 ℃. Cip release was quantified at selected time 
points by measuring the supernatant absorbance at 330 nm (U-3010, Hitachi High-
Technologies Corporation, Japan). Following 21-day incubation in PBS, fibres were rinsed 
with distilled water, dried and weighed, to quantify any sample mass loss [4]. 
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3.!Results and discussion  
A multiscale integrated process of Cip encapsulation, CTH in-situ crosslinking and wet 
spinning was developed aiming at mechanically-competent fibres with antibacterial 
functionality for medical devices (Figure 1).  
 
 
In-situ crosslinking was pursued during wet spinning to enhance the spinnability of CTH 
suspension, enable homogeneous crosslink density in fibre-forming CTHs, and control 
fibre’s release capability via Ph-Cip p-p aromatic interactions. NHS-activated Ph was reacted 
with CTHs in the absence (i) or presence (ii) of bME, whilst carbodiimide-induced 
crosslinking reaction (iii) was carried out as state-of-the-art reaction control. Therefore, 
covalent networks of CTHs crosslinked with (i) both EDC-induced amide bonds and 
Ph-based aromatic junctions, (ii) Ph-based aromatic junctions only, and (iii) EDC-induced 
amide bonds only (iii), were expected in resulting fibres. 
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Figure 1. Multiscale integrated process yielding mechanically-competent fibres as antibacterial-releasing
wrapping material for medical devices. In-situ crosslinking of wet spinning CTHs was pursued via reaction with
NHS-activated Ph in the absence (i) or presence (ii) of bME, and via control EDC-induced condensation reaction
(iii). Ph was selected to mediate p-p aromatic interactions with Cip and to control fibre’s drug release capability.
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Wet spun fibres were successfully realised with all three in-situ crosslinking strategies, 
whereby an averaged degree of collagen functionalisation (F) was measured via TNBS assay 
in the range of 50-67 mol.% (Figure 1). CF-Ph* obtained via (i) displayed comparable F with 
respect to EDC-crosslinked collagen fibre controls (CF-EN) deriving from (iii); whilst the 
highest value of F was recorded in fibres CF-Ph crosslinked via (ii) with Ph-based aromatic 
junctions only. Given that comparable molar crosslinker ratios were used in (i-iii), above-
mentioned F trends reflect selected crosslinking mechanisms. Reaction of collagen with 
NHS-activated Ph leads to lysine functionalisation with an aromatic residue and increased 
probability of crosslinking distant CTHs [11]; whilst zero-length crosslinks are generated via 
EDC-induced crosslinking reaction control [12], so that steric effects play a major role on 
the crosslinking yield. When Ph-mediated in-situ crosslinking of CTHs is carried out 
concomitantly to EDC-induced condensation reaction (in the absence of bME), the 
competition between theSE two reactions is likely to explain the reduced degree of 
functionalisation in fibres CF-Ph* with respect to fibres CF-Ph.  
Other than the molecular scale, resulting fibres displayed uniform surface morphology 
under SEM (Figure 2 A). A diameter of ~90 µm was measured, whereby minimal surface 
and diameter variations were observed with respect to the case of non-crosslinked, Cip-free 
fibre obtained via wet spinning of the same collagen suspension (Figure 2 B). This 
observation provides evidence that neither the introduction of a covalent network at the 
molecular scale or the encapsulation with Cip impacted on wet spun fibre microscale. 
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At the macroscale, the tensile modulus (E) and maximal tensile stress (smax) of the Cip-
encapsulated in-situ crosslinked fibres were measured in the range of 2100-2900 MPa and 
75-100 MPa, respectively (Figure 2 C). Samples Cip-CF-Ph revealed the highest averaged 
values (E: 2824 MPa; smax: 98 MPa), which proved to be statistically different to those of the 
control group Cip-CF-EN. The higher values of tensile properties measured in fibres Cip-
CF-Ph compared to controls Cip-CF-EN and, to a lesser extent, to fibres Cip-CF-Ph*, reflects 
the above-mentioned considerations in the network configuration introduced at the molecular 
scale of the wet spun fibres (Figure 1). Intermolecular crosslinks are selectively formed in 
the former samples following nucleophilic addition of collagen amine terminations with 
(C) (D)
Figure 2. (A-B): SEM images of fibre Cip-CF-Ph (A) and non-crosslinked Cip-free control (B). (C): Tensile
modulus (E, grey) and maximal tensile stress (smax, light grey) of Cip-encapsulated in-situ crosslinked wet
spun collagen fibres. (D): Stress-strain curves of fibres CF-Ph with (···) and without (―) Cip encapsulation.
100 µm100 µm
(A) (B)
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activated Ph carboxylic groups, in contrast to the latter groups [4,11,12]. The superior tensile 
mechanical properties of the Ph-crosslinked fibres are also supported by the increased degree 
of functionalisation in samples CF-Ph compared to controls CF-EN (Figure 1), indirectly 
suggesting the formation of covalent networks with increased crosslink density and p-p 
aromatic interactions between Ph-functionalised CTHs [11]. When comparing Cip-free and 
Cip-encapsulated fibres CF-Ph, a significantly decreased strain at break (eb) and 
insignificantly lower tensile stress were recorded in the latter compared to the former group 
(Figure 2 D). These results could be due to the Cip-induced plasticising effect of resulting 
fibres, due to the establishment of Cip-Ph rather than Ph-Ph p-p aromatic stacking 
interactions. 
Figure 3 (A) reports the temporal release profile of Cip following fibre incubation in PBS. 
Significant differences in fibre release capability were observed depending on the in-situ 
crosslinking strategy adopted during fibre wet spinning. In situ CTH crosslinking via 
simultaneous Ph-induced functionalisation and control EDC-mediated condensation 
reactions, on the one hand, and selective Ph-induced functionalisation reaction, on the other 
hand, successfully led to collagen fibres with increased temporal retention of Cip, indirectly 
supporting the establishment of p-p aromatic interactions between Ph-crosslinked CTHs and 
Cip. In the first hour, both Ph-reacted samples showed reduced release of Cip by more than 
50 % compared to the Ph-free control group. Within 8 hours, control fibres Cip-CF-EN 
displayed nearly complete release of Cip, whereas fibres Cip-CF-Ph* and Cip-CF-Ph still 
proved to retain ~40 % and ~50 % of the drug, respectively. Overall, the release rate was 
found to be decreased following 2.5-hour incubation of all groups, likely due to the initial 
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water-induced swelling of the dry collagen fibres and diffusion of Cip molecules coating the 
fibre surface. 
 
 
Other than the release capability, the hydrolytic degradability of collagen fibres was also 
investigated by gravimetric analysis (Figure 3 B). Samples CF-Ph described the highest mass 
loss, followed by control samples CF-EN and fibres CF-Ph*, a result which appeared to be 
in disagreement with the increased degree of collagen functionalisation (Figure 1) and tensile 
properties (Figure 2 C) of the former compared to the latter samples. The most likely 
explanation for this finding is that the addition of bME soon after Ph activation (Figure 1, ii) 
shifted the functionalisation reaction towards grafting rather than crosslinking, so that an 
increased content of Ph-grafted CTHs was generated at the molecular scale of fibres CF-Ph.  
 
4.!Conclusions  
A multiscale integrated process of ciprofloxacin encapsulation, in-situ crosslinking, and 
wet spinning was successfully developed to realise collagen fibres as medical devices with 
Figure 3. (A): Cip release profiles recorded following incubation of Cip-encapsulated fibres in vitro (PBS, 37
⁰C). (―■―): Cip-CF-EN; (−−!−−): Cip-CF-Ph*; (−−▲−−): Cip-CF-Ph. (B): Mass loss measured following 21-
day incubation of Cip-encapsulated fibres in vitro (PBS, 37 ⁰C).
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antibacterial release functionality. Fibre’s Cip release capability proved to be regulated at the 
nanoscale via the establishment of p-p aromatic interactions between the encapsulated drug 
and aromatised and crosslinked CTHs. In-situ crosslinked wet spun collagen fibres revealed 
homogeneous surface morphology with a diameter of ~90 µm, similarly to the case of non-
crosslinked wet spun controls. The highest tensile modulus and strength were measured in 
wet spun fibres selectively crosslinked with Ph, in line with the increased degree of collagen 
functionalisation.  
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